XTalks

JANUARY 26, 2023

This is the fourth US FDA approval that BeiGene has received for Brukinsa since 2019. Results from the SEQUOIA study demonstrated a significant progression-free survival benefit (Hazard Ratio: 0.42 [95 percent CI: 0.28, 0.63]; p < 0.0001) in CLL or SLL patients taking Brukinsa with a median follow-up of 26.2 percent vs 72.9

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

The Pharma Data

JANUARY 13, 2021

–( BUSINESS WIRE )– BeiGene, Ltd. This approval for tislelizumab is an important milestone for BeiGene, for tislelizumab, and for the patients and healthcare practitioners in China fighting advanced squamous NSCLC,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene. About BeiGene.

Production 52

Production Trials Antibody Clinical Trials 52

The Pharma Data

DECEMBER 27, 2020

–( BUSINESS WIRE )– BeiGene, Ltd. General Manager of China and President of BeiGene. “We With these NRDL inclusions, BeiGene is making significant strides towards our mission, which at its core is to expand access to and improve affordability of impactful innovative medicines for patients around the world. .

Production 52

Production Drugs Clinical Trials Clinical Trials 52